spacer
home > ict > spring 2020 > pushing ‘go’ again on clinical trials in a post-covid-19 world
PUBLICATIONS
International Clinical Trials

Pushing ‘Go’ Again on Clinical Trials in a Post-COVID-19 World



When the word ‘coronavirus’ entered the general consciousness in early 2020, little did we know the extent to which this new disease would essentially press pause on our daily lives. The true ramifications of lockdowns, social distancing, self-isolation, as well as hospital closures caused by the pandemic are as yet unknown, and will likely reverberate for a generation.

What we do know is across several weeks of firefighting to respond to the immediate situation, clinical trial sponsors have not yet got to thinking about what happens next. Clearly the current challenges are daunting. There’s a lot that needs to happen before we start thinking about patients travelling to sites again for their regular visits, but it’s worth starting to consider what happens when pharma companies do decide to press the ‘go’ button again.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

Illingworth Research Group is a provider of patient-centric clinical research solutions. This can be, but is not exclusive to, mobile research nursing, patient concierge, and medical photography. Services are operational in 45 countries and concentrate on taking the trial to the patient or making trial participation easier and more accessible to patients and their families. illingworthresearch.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Paris, France, 4th May 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will be presented at the 2022 American Society of Cell & Gene Therapy (ASCGT) meeting, which will be held virtually and in person in Washington, D.C., 16 to 19 May.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement